COMMUNIQUÉS West-GlobeNewswire

Horizon Discovery appoints Terry Pizzie as Chief Executive Officer
08/05/2018
Horizon Discovery Group plc Horizon Discovery appoints Terry Pizzie as Chief Executive Officer Cambridge, UK, 8 May 2018: Horizon Discovery Group plc (LSE: HZD) ("Horizon", "the Group" or "the Company"), a global leader [...]
Sernova Announces U.S. Phase I/II Cell Pouch Clinical Trial with Prominent Diabetes Clinical Investigator
08/05/2018
Leading Surgeon and Researcher in Islet Transplantation at the University of Chicago to act as Clinical Trial Principal Investigator. Study to focus on severely diabetic patients with hypoglycemia unawareness LONDON, [...]
CureVac Announces New Management Structure
08/05/2018
Founder Ingmar Hoerr to transition to Chairman role; Daniel Menichella to become CEO TÜBINGEN, Germany and BOSTON, May 08, 2018 (GLOBE NEWSWIRE) -- CureVac AG, a fully-integrated biopharmaceutical company pioneering the [...]
Invivoscribe Submits Pre-Market Approval Application in Japan and Panel Track Supplement in the US to Screen Acute Myeloid Leukemia (AML) Patients for FLT3 Mutations
08/05/2018
SAN DIEGO, May 08, 2018 (GLOBE NEWSWIRE) -- Invivoscribe Technologies, Inc. announced today that they have submitted to Japan’s Pharmaceutical and Medical Devices Agency (PMDA) and the US Food and Drug Administration ( [...]
BioCryst Reports First Quarter 2018 Financial Results
08/05/2018
RESEARCH TRIANGLE PARK, N.C., May 08, 2018 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (NASDAQ: BCRX ) announced today financial results for the first quarter ended March 31, 2018. “We are off to a strong start [...]
Mesoblast Phase 3 Trial Results for Acute Graft Versus Host Disease Presented at 2018 International Society for Cell and Gene Therapy Annual Meeting
08/05/2018
NEW YORK and MELBOURNE, Australia, May 08, 2018 (GLOBE NEWSWIRE) -- Mesoblast Limited (Nasdaq: MESO ) (ASX:MSB) today announced that results of the Phase 3 trial evaluating its product candidate MSC-100-IV (remestemcel- [...]
PotNetwork Holdings, Inc. Announces Partial Debt Retirement of $1.2 Million
08/05/2018
With $6.3 Million in Revenues for Q1 of 2018, and Steps Taken to Reduce Debt, Company on Clear Track to Outperform 2017 FORT LAUDERDALE, Fla., May 08, 2018 (GLOBE NEWSWIRE) -- PotNetwork Holdings, Inc. (OTC Pink:POTN) [...]
Cellular Biomedicine Group Reports First Quarter 2018 Financial Results and Highlights Operational Progress
08/05/2018
China Food and Drug Administration Accepts the Company’s Investigational New Drug (IND) Applications for anti-CD19 CAR-T Therapy Targeting NHL and ALL Positive 48-Week Phase I Clinical Data of AlloJoin TM haMPC therapy [...]
CV Sciences, Inc. to Host First Quarter 2018 Financial Results Conference Call on Tuesday, May 15, 2018
08/05/2018
LAS VEGAS, May 08, 2018 (GLOBE NEWSWIRE) -- CV Sciences, Inc. , (OTCQB:CVSI) a preeminent manufacturer and distributor of hemp-derived phytocannabinoids including CBD oil, today announced that it is scheduled to host a [...]
RECORDATI ANNOUNCES SALES AND MARGIN GROWTH IN THE FIRST QUARTER 2018. REVENUES +7.2%, OPERATING INCOME +12.4%, NET INCOME +10.3%
08/05/2018
Consolidated revenues € 366.5 million, +7.2%. EBITDA (1) € 134.4 million, +14.2% Operating income € 120.5 million, +12.4%. Net income € 86.6 million, +10.3%. Net financial position (2) : net debt of € 484.6 million. [...]
Trading by management and close relations of management
08/05/2018
Read the full announcement in the attached file Attachment 2018_28_Trading_by_management_EN
Affimed Announces First Quarter 2018 Financial Results and Corporate Update Conference Call
08/05/2018
Heidelberg, Germany, May 8, 2018 - Affimed N.V. (Nasdaq: AFMD), a clinical stage biopharmaceutical company focused on discovering and developing highly targeted cancer immunotherapies, today announced that on May 15, [...]
argenx announces results of Annual General Meeting of Shareholders
08/05/2018
May 8, 2018 Breda, the Netherlands / Ghent, Belgium - argenx (Euronext & Nasdaq: ARGX), a clinical-stage biotechnology company developing a deep pipeline of differentiated antibody-based therapies for the treatment [...]
Probiodrug positioning its pGlu-Abeta Antibody in the field of Abeta antibodies
08/05/2018
Probiodrug positioning its pGlu-Abeta Antibody in the field of Abeta antibodies Probiodrug co-authored a review paper entitled "Passive Abeta Immunotherapy: Current Achievements and Future Perspectives " HALLE (SAALE), [...]
Notification from Oasmia Pharmaceutical AB
08/05/2018
Oasmia Pharmaceutical AB hereby issues a notification that EMA has given 60 days response time instead of 30 days as previously communicated and requested by the company. Oasmia will respond to the list of issues [...]
Shire plc : Rule 2.9 Announcement
08/05/2018
NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION IN WHOLE OR IN PART IN, INTO OR FROM ANY JURISDICTION WHERE TO DO SO WOULD CONSTITUTE A VIOLATION OF THE RELEVANT LAWS OR REGULATIONS OF THAT JURISDICTION. 8 May 2018 Shire [...]
Motif Bio to Present Iclaprim Data at ASM Microbe 2018
08/05/2018
NEW YORK, May 08, 2018 (GLOBE NEWSWIRE) -- Motif Bio plc (AIM:MTFB) (NASDAQ: MTFB ), a clinical-stage biopharmaceutical company specialising in developing novel antibiotics, today announced that two iclaprim abstracts [...]
Verona Pharma plc Operational Update and Financial Results for the First Quarter Ended March 31, 2018
08/05/2018
Announced positive top-line data from two Phase 2 clinical trials ahead of schedule Met primary and key secondary endpoints in 403 patient Phase 2b clinical trial for maintenance treatment of COPD Met primary and [...]
William Demant Holding A/S: Interim Management Statement covering the period year-to-date
08/05/2018
Company announcement no 2018-06 8 May 2018 Continued strong performance by the Group in line with our expectations Innovative products driving strong organic growth in hearing aid wholesale business 2018 outlook [...]

Pages